Predictive accuracy of fecal calprotectin in assessing clinical activity and disease severity in patients with Ulcerative Colitis and Crohn’s disease
Open Access
- 4 June 2025
- journal article
- research article
- Published by Springer Nature in BMC Gastroenterology
- Vol. 25 (1) , 1-9
Abstract
Background: Inflammatory bowel disease (IBD) is an idiopathic disorder characterized by repeated relapses and remissions. Endoscopy, the gold standard for diagnosis and monitoring of these patients is time consuming, expensive, and invasive. Hence, faecal calprotectin (FCP) has been suggested as marker to determine the degree of intestinal inflammation and predict relapse in IBD. Objective: To use FCP as a predictor of clinical activity and endoscopic severity in IBD patients in a tertiary care hospital in Southern India. Methods: Study subjects underwent clinical examination, endoscopy, blood tests and stool FCP. For Endoscopic activity simple endoscopic score for Crohn’s disease (SES-CD) and Ulcerative Colitis endoscopic index of severity (UCEIS) scores were used, and clinical activity was assessed by Crohn’s disease activity index (CDAI) and simple clinical colitis index (SCCAI) for CD and UC respectively. At six months, blood, and stool FCP test were repeated which were compared with endoscopic and clinical activity indices. Results: The number of males was higher in both CD (13/8) and UC (19/14). At first visit and follow up, CDAI and FCP were positively correlated (r-0.689, p- 0.016) (r- 0.425, p-value < 0.05). In CD, the sensitivity and specificity of FCP in detecting active disease and remission were 93.8% and 80% respectively (AUC-0.869). At follow up, the sensitivity and specificity were 80% and 93.3% respectively (AUC-0.867). In patients with UC, SCCAI score and FCP levels positively correlated (r-0.231/0.387, p-value 0.001/0.001) at both the first and follow up visits. The sensitivity of FCP in detecting UC in active and remission states was 92.6% whereas the specificity was 83.3%. AUC was 0.88. At the time of follow up, the sensitivity of FCP in detecting UC in active and remission states was 89.9% whereas the specificity was 87.0% and AUC was 0.879. Conclusion: This study confirmed that FCP level shows strong association with clinical and endoscopic activity indices in patients of IBD. Therefore, FCP levels could be used as a surrogate marker for monitoring mucosal status as well as predicting endoscopic remission in IBD patients.Keywords
Funding Information
- Manipal Academy of Higher Education - Kasturba Medical College, Mangalore
This publication has 26 references indexed in Scilit:
- Trends of inflammatory bowel disease from the Global Burden of Disease Study (1990-2019)Indian Journal of Gastroenterology, 2023
- COVID-19 pandemic and inflammatory bowel disease from patients' perspective: A survey from COVID epicenter in IndiaJGH Open, 2022
- STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBDGastroenterology, 2021
- ECCO-ESGAR Guideline for Diagnostic Assessment in IBD Part 2: IBD scores and general principles and technical aspectsJournal of Crohn's and Colitis, 2018
- Results of the 2nd part Scientific Workshop of the ECCO (II): Measures and markers of prediction to achieve, detect, and monitor intestinal healing in Inflammatory Bowel DiseaseJournal of Crohn's and Colitis, 2011
- Assessment of endoscopic activity index and biological inflammatory markers in clinically active Crohnʼs disease with normal C-reactive protein serum levelInflammatory Bowel Diseases, 2007
- A Meta-Analysis of the Placebo Rates of Remission and Response in Clinical Trials of Active Ulcerative ColitisGastroenterology, 2007
- Role of fecal calprotectin as a biomarker of intestinal inflammation in inflammatory bowel diseaseInflammatory Bowel Diseases, 2006
- Development and validation of a new, simplified endoscopic activity score for Crohn's disease: the SES-CDGastrointestinal Endoscopy, 2004
- Medical management of severe ulcerative colitisGastroenterology Clinics of North America, 2004